Clinical Trial Update: Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial of the carboplatin–etoposide combination for hormone-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: Centre Leon Berard | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED